Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis

被引:4
|
作者
Gao, Fenghua [1 ]
Zhang, Tingting [1 ]
Liu, Hengqi [1 ]
Li, Wei [1 ]
Liu, Xianming [1 ]
Qiu, Lihua [1 ]
Li, Lanfang [1 ]
Zhou, Shiyong [1 ]
Qian, Zhengzi [1 ]
Dong, Sitong [2 ]
Zhao, Sai [2 ]
Wang, Xianhuo [1 ]
Zhang, Huilai [1 ]
机构
[1] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc,Dept Lymphoma, Sino US Ctr Lymphoma & Leukemia Res,Key Lab Canc, Huanhuxi Rd, Tianjin 300060, Peoples R China
[2] Systemat Review Solut Ltd, Ingenu Ctr, Nottingham, England
基金
中国国家自然科学基金;
关键词
Follicular lymphoma; POD24; Risk factors; Meta-analysis; Systematic review; SOLUBLE INTERLEUKIN-2-RECEPTOR LEVEL; METABOLIC TUMOR VOLUME; RITUXIMAB PLUS CYCLOPHOSPHAMIDE; PROGRESSION-FREE SURVIVAL; MINIMAL RESIDUAL DISEASE; PROGNOSTIC VALUE; 1ST-LINE TREATMENT; PREDICTS SURVIVAL; DIAGNOSIS; DOXORUBICIN;
D O I
10.1007/s00277-022-04914-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Progression of disease within 24 months (POD24) is strongly associated with a poor outcome in patients with follicular lymphoma (FL). Our study aimed to identify the potential risk factors for POD24 in patients with FL. Medline, EMBASE and the Cochrane Library were systematically searched from the earliest record to September 2020. Studies investigating the prognostic factors for POD24 in patients with newly diagnosed grade 1-3a FL were included. Among 10,014 pieces of literature, a total of 90 studies investigating 82 risk factors were included for qualitative analysis. Meta-analyses were performed in 31 studies with 11 factors. Results showed that elevated sIL-2R, beta 2m and LDH, total metabolic tumour volume > 510 cm(3), vitamin D < 20 ng/mL, grade 3a and lymphoma-associated macrophages/high-power field >= 15 were significantly associated with an increased risk of POD24. No significant association was found between POD24 and the ALC/AMC ratio, sex, T effector signature or EZH2 genetic alteration. Additionally, minimal residual disease, Ki-67, PD-1 and TP53 were analysed narratively. Overall, this is the first study that comprehensively analysed the prognostic factors associated with POD24 in FL patients. We have confirmed the significance value of several common prognostic factors as well as others not commonly included in clinical study, helping to construct an integrated and more efficient model.
引用
收藏
页码:2383 / 2392
页数:10
相关论文
共 50 条
  • [21] Therapy for patients with POD24 follicular lymphoma: Treatment patterns and outcomes from the Lymphoma Epidemiology of Outcomes (LEO) Consortium.
    Casulo, Carla
    Larson, Melissa C.
    Day, Jonathan R.
    Habermann, Thomas Matthew
    Lossos, Izidore S.
    Wang, Yucai
    Nastoupil, Loretta J.
    Strouse, Christopher
    Chihara, Dai
    Martin, Peter
    Cohen, Jonathon Brett
    Kahl, Brad S.
    Ruan, Jia
    Burack, Walter Richard
    Koff, Jean Louise
    Friedberg, Jonathan W.
    Cerhan, James Robert
    Flowers, Christopher
    Link, Brian K.
    Maurer, Matthew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [22] Effectiveness of Targeted Therapy in Patients With Previously Untreated Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
    Kawalec, Pawel
    Lopuch, Sylwia
    Mikrut, Alicja
    CLINICAL BREAST CANCER, 2015, 15 (02) : 90 - U181
  • [23] Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
    Zeng, Zhiyong
    Lin, Junfang
    Chen, Junmin
    ANNALS OF HEMATOLOGY, 2013, 92 (07) : 935 - 943
  • [24] Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
    Zhiyong Zeng
    Junfang Lin
    Junmin Chen
    Annals of Hematology, 2013, 92 : 935 - 943
  • [25] Progression of disease within 24 months (POD24) in follicular lymphoma in the rituximab era: incidence, clinicopathological risk factors, and outcome in a population-based Danish cohort
    Marie Hairing Enemark
    Jonas Klejs Hemmingsen
    Maja Dam Andersen
    Trine Engelbrecht Hybel
    Mads Emil Bjørn
    Pär Lars Josefsson
    Lars Møller Pedersen
    Maja Bech Juul
    Robert Schou Pedersen
    Michael Thorsgaard
    Ida Blok Sillesen
    Trine Lindhardt Plesner
    Stephen Jacques Hamilton-Dutoit
    Paw Jensen
    Charlotte Madsen
    Maja Ludvigsen
    Blood Cancer Journal, 14 (1)
  • [26] Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized Trials
    Vidal, Liat
    Gafter-Gvili, Anat
    Leibovici, Leonard
    Dreyling, Martin
    Ghielmini, Michele
    Schmitz, Shu-Fang Hsu
    Cohen, Amos
    Shpilberg, Ofer
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (04): : 248 - 255
  • [27] Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis
    Simone Lanini
    Aoife C Molloy
    Paul E Fine
    Archibald G Prentice
    Giuseppe Ippolito
    Christopher C Kibbler
    BMC Medicine, 9
  • [28] Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis
    Lanini, Simone
    Molloy, Aoife C.
    Fine, Paul E.
    Prentice, Archibald G.
    Ippolito, Giuseppe
    Kibbler, Christopher C.
    BMC MEDICINE, 2011, 9
  • [29] Risk factors for patients with tracheal stenosis: a systematic review and meta-analysis
    Hong, Siqi
    Wu, Xiaobing
    Feng, Haihuan
    Zhang, Qing
    Wang, Xiaohan
    Chang, Minmin
    Chen, Xiuli
    Liu, Weijuan
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2024, 52 (09)
  • [30] Risk Factors for Survival in Patients With Medulloblastoma: A Systematic Review and Meta-Analysis
    Liu, Yu
    Xiao, Bo
    Li, Sen
    Liu, Jiangang
    FRONTIERS IN ONCOLOGY, 2022, 12